IL163995A0 - N3 alkylated benzimidazole derivatives as mek inhibitors - Google Patents

N3 alkylated benzimidazole derivatives as mek inhibitors

Info

Publication number: IL163995A0
Authority: IL; Israel
Prior art keywords: benzimidazole derivatives; mek inhibitors; alkylated benzimidazole; alkylated; mek
Prior art date: 2002-03-13

Application number

IL16399503A

Other languages

English (en)

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-13

Filing date

2003-03-13

Publication date

2005-12-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL163995(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-13 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2005-12-18 Publication of IL163995A0 publication Critical patent/IL163995A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

IL16399503A 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivatives as mek inhibitors IL163995A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36400702P	2002-03-13	2002-03-13
PCT/US2003/007864 WO2003077914A1 (en)	2002-03-13	2003-03-13	N3 alkylated benzimidazole derivatives as mek inhibitors

Publications (1)

Publication Number	Publication Date
IL163995A0 true IL163995A0 (en)	2005-12-18

Family

ID=28041856

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
IL16399503A IL163995A0 (en)	2002-03-13	2003-03-13	N3 alkylated benzimidazole derivatives as mek inhibitors
IL163995A IL163995A (en)	2002-03-13	2004-09-09	N3 alkylated benzimidazole derivatives as mek inhibitors
IL204420A IL204420A (en)	2002-03-13	2010-03-10	6– (4 – bromo – 2 – chloro – phenylamino) –7 – fluoro – 3 – methyl– H3– benzoimidazole – 5 – carboxylic acid (2 – hydroxy – ethoxy) –amide
IL204419A IL204419A (en)	2002-03-13	2010-03-10	Derivatives of benzoimidazole-5-rich carboxylic acid

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
IL163995A IL163995A (en)	2002-03-13	2004-09-09	N3 alkylated benzimidazole derivatives as mek inhibitors
IL204420A IL204420A (en)	2002-03-13	2010-03-10	6– (4 – bromo – 2 – chloro – phenylamino) –7 – fluoro – 3 – methyl– H3– benzoimidazole – 5 – carboxylic acid (2 – hydroxy – ethoxy) –amide
IL204419A IL204419A (en)	2002-03-13	2010-03-10	Derivatives of benzoimidazole-5-rich carboxylic acid

Country Status (35)

Country	Link
US (11)	US20030232869A1 (xx)
EP (5)	EP3000810B1 (xx)
JP (4)	JP4093966B2 (xx)
KR (3)	KR100984613B1 (xx)
CN (4)	CN101633644B (xx)
AR (3)	AR038971A1 (xx)
AT (1)	ATE449605T1 (xx)
AU (2)	AU2003218157C1 (xx)
BE (1)	BE2019C510I2 (xx)
BR (1)	BR122018007328B8 (xx)
CA (1)	CA2478374C (xx)
CL (2)	CL2012002381A1 (xx)
CY (3)	CY1109727T1 (xx)
DE (1)	DE60330227D1 (xx)
DK (4)	DK2275102T3 (xx)
DO (4)	DOP2003000613A (xx)
ES (5)	ES2407849T3 (xx)
HK (3)	HK1070823A1 (xx)
HU (2)	HUE025767T2 (xx)
IL (4)	IL163995A0 (xx)
IS (4)	IS2748B (xx)
LT (1)	LTC1482932I2 (xx)
LU (1)	LUC00100I2 (xx)
MX (1)	MXPA04008893A (xx)
NL (1)	NL300974I2 (xx)
NZ (1)	NZ535158A (xx)
PA (1)	PA8569301A1 (xx)
PL (5)	PL233493B1 (xx)
PT (4)	PT1482932E (xx)
SG (3)	SG148857A1 (xx)
SI (4)	SI2130537T1 (xx)
TW (3)	TWI350285B (xx)
UA (1)	UA77765C2 (xx)
WO (1)	WO2003077914A1 (xx)
ZA (1)	ZA200407220B (xx)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG148857A1 (en) *	2002-03-13	2009-01-29	Array Biopharma Inc	N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003297925A1 (en) *	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Thrombopoietin mimetics
EP1598079B1 (en) *	2003-02-26	2009-04-22	Kowa Co., Ltd.	Remedies for allergic contact dermatitis
CA2532067C (en)	2003-07-24	2010-12-21	Stephen Douglas Barrett	N-methyle-substituted benzamidazoles
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en)	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
JP5042626B2 (ja)	2003-09-22	2012-10-03	エス＊バイオプライベートリミティッド	ベンズイミダゾール誘導体：製造及び医薬適用
AU2004293019B2 (en) *	2003-11-19	2010-10-28	Array Biopharma Inc.	Bicyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) *	2003-11-19	2009-04-14	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en)	2003-11-19	2010-06-08	Array Biopharma Inc.	Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
KR101223914B1 (ko) *	2003-11-21	2013-01-18	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제
EP1699477A2 (en) *	2003-12-11	2006-09-13	Theravance, Inc.	Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7956191B2 (en)	2004-10-20	2011-06-07	Merck Serono Sa	3-arylamino pyridine derivatives
ATE443063T1 (de) *	2004-12-01	2009-10-15	Merck Serono Sa	Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
US7429667B2 (en) *	2005-01-20	2008-09-30	Ardea Biosciences, Inc.	Phenylamino isothiazole carboxamidines as MEK inhibitors
TWI441637B (zh)	2005-05-18	2014-06-21	Array Biopharma Inc	Ｍｅｋ雜環抑制劑及其使用方法
AU2006262259B2 (en) *	2005-06-23	2013-03-14	Array Biopharma Inc.	Process for preparing benzimidazole compounds
CA2612296A1 (en) *	2005-06-23	2007-01-04	Array Biopharma Inc.	Snar process for preparing benzimidazole compounds
US8101799B2 (en)	2005-07-21	2012-01-24	Ardea Biosciences	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EA019983B1 (ru)	2005-10-07	2014-07-30	Экселиксис, Инк.	Ингибиторы mek и способы их применения
AU2013203939B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
AU2012261703B2 (en) *	2005-10-07	2015-08-13	Exelixis, Inc.	Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7968108B2 (en) *	2005-10-25	2011-06-28	Metbro Distributing L.P.	Hydrogen cyanamide pesticide formulations
US7572460B2 (en) *	2005-10-25	2009-08-11	Rodrigo Rodriguez-Kabana	Hydrogen cyanamide pesticide formulations
EP1966155A1 (en) *	2005-12-21	2008-09-10	AstraZeneca AB	Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
CA2534243A1 (fr)	2006-01-25	2007-07-25	Hydro Quebec	Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en)	2006-01-31	2006-03-15	Ucb Sa	Therapeutic agents
WO2007121269A2 (en)	2006-04-11	2007-10-25	Ardea Biosciences, Inc.	N-aryl-n'alkyl sulfamides as mek inhibitors
JP5269762B2 (ja) *	2006-04-18	2013-08-21	アーディア・バイオサイエンシーズ・インコーポレイテッド	Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド
MY147628A (en)	2006-07-06	2012-12-31	Array Biopharma Inc	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
DE602007011628D1 (de)	2006-07-06	2011-02-10	Array Biopharma Inc	Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
WO2008006039A1 (en)	2006-07-06	2008-01-10	Array Biopharma Inc.	Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008016123A1 (fr) *	2006-08-03	2008-02-07	Takeda Pharmaceutical Company Limited	INHIBITEUR DE LA GSK-3β
CN101583616B (zh) *	2006-08-21	2012-05-30	健泰科生物技术公司	氮杂苯并噻吩基化合物及使用方法
ES2528797T3 (es)	2006-08-21	2015-02-12	Genentech, Inc.	Compuestos de aza-benzotiofenilo y métodos de uso
US20080085886A1 (en) *	2006-08-21	2008-04-10	Genentech, Inc.	Aza-benzofuranyl compounds and methods of use
CA2671982C (en)	2006-12-14	2016-01-26	Exelixis, Inc.	Methods of using mek inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
CN101678001A (zh) *	2007-04-13	2010-03-24	阿斯利康(瑞典)有限公司	包含azd2171和azd6244或mek-抑制剂ⅱ的组合治疗
US8509487B2 (en) *	2007-04-19	2013-08-13	Avago Technologies General Ip (Singapore) Pte. Ltd.	System and method for optically measuring a parameter of an object
JP5580735B2 (ja)	2007-06-12	2014-08-27	ジェネンテック，インコーポレイテッド	Ｎ−置換アザインドール類及び使用方法
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN103396409B (zh)	2007-07-05	2015-03-11	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CA2692506C (en)	2007-07-05	2015-11-24	Array Biopharma Inc.	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
GB0714384D0 (en)	2007-07-23	2007-09-05	Ucb Pharma Sa	theraputic agents
BRPI0818426A2 (pt) *	2007-10-15	2017-06-13	Astrazeneca Ab	produto de combinação, uso de um produto de combinação, e, método para tratar câncer
US8022057B2 (en)	2007-11-12	2011-09-20	Takeda Pharmaceutical Company Limited	MAPK/ERK kinase inhibitors
CA2706571C (en)	2007-12-19	2012-11-27	Genentech, Inc.	5-anilinoimidazopyridines and methods of use
AU2008343062B2 (en)	2007-12-19	2013-03-07	Genentech, Inc.	8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
BRPI0820696A2 (pt)	2007-12-20	2019-09-24	Hoffmann La Roche	hidantoínas substituídas como inibidores de cinase de mek
KR20100099185A (ko)	2007-12-21	2010-09-10	제넨테크, 인크.	아자인돌리진 및 이용 방법
CA2711699A1 (en)	2008-01-09	2009-07-16	Array Biopharma Inc.	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2240455B1 (en)	2008-01-09	2012-12-26	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
EP2240494B1 (en)	2008-01-21	2016-03-30	UCB Biopharma SPRL	Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en)	2008-06-19	2008-07-30	Ucb Pharma Sa	Therapeutic agents
JP5404622B2 (ja)	2008-06-23	2014-02-05	パナソニック株式会社	無線通信基地局装置および参照信号割当方法
JP5615274B2 (ja) *	2008-07-01	2014-10-29	ジェネンテック，インコーポレイテッド	Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
US8841462B2 (en)	2008-07-01	2014-09-23	Robert A. Heald	Bicyclic heterocycles as MEK kinase inhibitors
BRPI0916566B8 (pt)	2008-08-04	2021-05-25	Merck Patent Ges Mit Beschraenkter Haftung	isonicotinamida fenilamina, seu uso, composição farmacêutica, e kit
CN101653607B (zh) *	2008-08-19	2013-02-13	鼎泓国际投资（香港）有限公司	含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
US8470819B2 (en) *	2008-11-03	2013-06-25	Merck Sharp & Dohme Corp.	Benzimidazole and aza-benzimidazole carboxamides
ES2399384T3 (es)	2008-11-10	2013-04-01	Bayer Schering Pharma Ag	Sulfonamido fenoxibenzamidas sustituidas
US8242260B2 (en)	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
CA2777430A1 (en)	2009-10-21	2011-04-28	Bayer Pharma Aktiengesellschaft	Substituted benzosulphonamides
EP2491014A1 (en)	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Substituted halophenoxybenzamide derivatives
US8962606B2 (en)	2009-10-21	2015-02-24	Bayer Intellectual Property Gmbh	Substituted benzosulphonamides
WO2011095807A1 (en)	2010-02-07	2011-08-11	Astrazeneca Ab	Combinations of mek and hh inhibitors
US9205086B2 (en)	2010-04-19	2015-12-08	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
MX2012015100A (es)	2010-06-25	2013-05-01	Novartis Ag	Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
KR20130113430A (ko)	2010-08-05	2013-10-15	케이스 웨스턴 리저브 유니버시티	신경 연결의 발달 장애에 대한 ｅｒｋ 억제제
ES2714384T3 (es)	2010-10-06	2019-05-28	Glaxosmithkline Llc	Derivados de bencimidazol como inhibidores de PI3 quinasa
WO2012055953A1 (en)	2010-10-29	2012-05-03	Bayer Pharma Aktiengesellschaft	Substituted phenoxypyridines
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN114164167A (zh)	2010-12-22	2022-03-11	菲特治疗公司	用于单细胞分选与增强ipsc重新编程的细胞培养平台
SI2655375T1 (sl)	2010-12-23	2015-03-31	Sanofi	Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
SG194048A1 (en)	2011-04-01	2013-11-29	Genentech Inc	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh)	2011-04-01	2014-06-04	基因泰克公司	Akt和mek抑制剂化合物的组合及其使用方法
WO2012145503A1 (en)	2011-04-21	2012-10-26	Novartis Ag	Pharmaceutical combinations
US20140228418A1 (en) *	2011-05-23	2014-08-14	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US9833439B2 (en)	2011-05-25	2017-12-05	Universite Paris Descartes	ERK inhibitors for use in treating spinal muscular atrophy
ES2671748T3 (es)	2011-07-21	2018-06-08	Tolero Pharmaceuticals, Inc.	Inhibidores heterocíclicos de proteína quinasas
TW201840336A (zh)	2011-08-01	2018-11-16	美商建南德克公司	利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US10314594B2 (en)	2012-12-14	2019-06-11	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
US10813630B2 (en)	2011-08-09	2020-10-27	Corquest Medical, Inc.	Closure system for atrial wall
US10307167B2 (en)	2012-12-14	2019-06-04	Corquest Medical, Inc.	Assembly and method for left atrial appendage occlusion
KR20140072028A (ko) *	2011-08-31	2014-06-12	노파르티스 아게	Pi3k- 및 mek-억제제의 상승작용적 조합물
BR112014002885A2 (pt)	2011-09-01	2017-02-21	Novartis Ag	uso de composto orgânico para o tratamento da síndrome de noonan
EP2570127A1 (en)	2011-09-16	2013-03-20	Sanofi	Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
CA2852060A1 (en)	2011-10-14	2013-04-18	Array Biopharma Inc.	Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
US9439899B2 (en)	2011-11-02	2016-09-13	Synta Pharmaceuticals Corp.	Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
CA2853806C (en)	2011-11-02	2020-07-14	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2780010A1 (en)	2011-11-14	2014-09-24	Synta Pharmaceuticals Corp.	Combination therapy of hsp90 inhibitors with braf inhibitors
US9220775B2 (en)	2011-11-23	2015-12-29	Medimmune Llc	Binding molecules specific for HER3 and uses thereof
WO2013082511A1 (en)	2011-12-02	2013-06-06	Genentech, Inc.	Methods for overcoming tumor resistance to vegf antagonists
US10023862B2 (en)	2012-01-09	2018-07-17	Arrowhead Pharmaceuticals, Inc.	Organic compositions to treat beta-catenin-related diseases
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204822B (zh)	2012-01-17	2014-12-03	上海科州药物研发有限公司	作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
MX359770B (es) *	2012-03-20	2018-10-10	Novartis Ag Star	Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
CN104350415B (zh)	2012-04-09	2018-01-16	思维奇材料公司	转换材料，及其组合物和制造方法
EP2856222A4 (en)	2012-05-29	2016-01-27	Switch Materials Inc	OPTICAL FILTER COMPRISING A VARIABLE TRANSMITTANCE LAYER
CN104394855A (zh)	2012-05-31	2015-03-04	拜耳医药股份有限公司	用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
KR20150038068A (ko)	2012-08-17	2015-04-08	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
MD20150043A2 (ro)	2012-10-02	2015-08-31	Epitherapeutics Aps	Inhibitori ai histon-demetilazelor
SI2909188T1 (en)	2012-10-12	2018-07-31	Exelixis, Inc.	A novel process for the manufacture of compounds for use in the treatment of cancer
US9394257B2 (en)	2012-10-16	2016-07-19	Tolero Pharmaceuticals, Inc.	PKM2 modulators and methods for their use
LT3702351T (lt) *	2012-10-19	2024-01-10	Array Biopharma, Inc.	Kompozicijos, apimančios mek inhibitorių
US20140142689A1 (en)	2012-11-21	2014-05-22	Didier De Canniere	Device and method of treating heart valve malfunction
RU2674995C2 (ru) *	2012-11-29	2018-12-14	Новартис Аг	Фармацевтические комбинации
EP2934515B1 (en)	2012-12-20	2018-04-04	Novartis AG	A pharmaceutical combination comprising binimetinib
EP2752191A1 (en)	2013-01-07	2014-07-09	Sanofi	Compositions and methods using hdm2 antagonist and mek inhibitor
CN105229144A (zh)	2013-02-22	2016-01-06	细胞动力学国际有限公司	通过组合的遗传工程和化学工程经由正向编程产生肝细胞
WO2014133071A1 (ja)	2013-02-27	2014-09-04	第一三共株式会社	Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
EP3170811A1 (en)	2013-02-27	2017-05-24	Gilead Sciences, Inc.	Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases
US10202356B2 (en)	2013-03-14	2019-02-12	Tolero Pharmaceuticals, Inc.	JAK2 and ALK2 inhibitors and methods for their use
SG10201906270VA (en) *	2013-03-21	2019-08-27	Novartis Ag	Combination therapy comprising a b-raf inhibitor and a second inhibitor
AR097617A1 (es)	2013-09-13	2016-04-06	Actelion Pharmaceuticals Ltd	Derivados antibacterianos del 2h-indazol
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
EP3049442A4 (en)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
US9566443B2 (en)	2013-11-26	2017-02-14	Corquest Medical, Inc.	System for treating heart valve malfunction including mitral regurgitation
JP6407288B2 (ja)	2013-12-19	2018-10-17	イドーシアファーマシューティカルズリミテッドＩｄｏｒｓｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
CN104788365B (zh) *	2014-01-16	2018-08-10	上海艾力斯医药科技有限公司	异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
AR099612A1 (es)	2014-03-04	2016-08-03	Actelion Pharmaceuticals Ltd	Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
SG11201606934SA (en)	2014-03-04	2016-09-29	Fate Therapeutics Inc	Improved reprogramming methods and cell culture platforms
CN106103484B (zh)	2014-03-14	2021-08-20	诺华股份有限公司	针对lag-3的抗体分子及其用途
WO2015153498A1 (en)	2014-03-31	2015-10-08	Epitherapeutics, Aps	Inhibitors of histone demethylases
WO2015164228A1 (en)	2014-04-21	2015-10-29	Cellular Dynamics International, Inc.	Hepatocyte production via forward programming by combined genetic and chemical engineering
EP3143007B1 (en)	2014-05-16	2018-07-11	Idorsia Pharmaceuticals Ltd	Antibacterial quinazoline-4(3h)-one derivatives
US10023879B2 (en)	2014-06-04	2018-07-17	Fate Therapeutics, Inc.	Minimal volume reprogramming of mononuclear cells
AU2015289672A1 (en)	2014-07-15	2017-03-02	Genentech, Inc.	Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
CN107074807A (zh)	2014-08-27	2017-08-18	吉利德科学公司	用于抑制组蛋白脱甲基酶的组合物和方法
US9993551B2 (en)	2014-09-13	2018-06-12	Novartis Ag	Combination therapies of EGFR inhibitors
KR20170066546A (ko)	2014-10-03	2017-06-14	노파르티스 아게	조합 요법
AU2015328411C1 (en)	2014-10-06	2022-03-03	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es)	2014-10-14	2017-11-07	Dana Farber Cancer Inst Inc	Moléculas de anticuerpo que se unen a pd-l1
US10842626B2 (en)	2014-12-09	2020-11-24	Didier De Canniere	Intracardiac device to correct mitral regurgitation
EP3233918A1 (en)	2014-12-19	2017-10-25	Novartis AG	Combination therapies
NZ731664A (en)	2014-12-23	2024-02-23	Novartis Ag	Triazolopyrimidine compounds and uses thereof
SG11201706041XA (en)	2015-01-26	2017-08-30	Fate Therapeutics Inc	Methods and compositions for inducing hematopoietic cell differentiation
CN105566225A (zh) *	2015-02-16	2016-05-11	苏州晶云药物科技有限公司	一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) *	2015-02-24	2016-09-01	学校法人兵庫医科大学	抗腫瘍効果増強剤および抗腫瘍剤
MY190404A (en)	2015-03-10	2022-04-21	Aduro Biotech Inc	Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
JP6695353B2 (ja)	2015-03-25	2020-05-20	ノバルティスアーゲー	Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
MA41866A (fr)	2015-03-31	2018-02-06	Massachusetts Gen Hospital	Molécules à auto-assemblage pour l'administration ciblée de médicaments
SI3317301T1 (sl)	2015-07-29	2021-10-29	Novartis Ag	Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP3316902A1 (en)	2015-07-29	2018-05-09	Novartis AG	Combination therapies comprising antibody molecules to tim-3
AR105646A1 (es)	2015-08-11	2017-10-25	Actelion Pharmaceuticals Ltd	Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
US20190008859A1 (en)	2015-08-21	2019-01-10	Acerta Pharma B.V.	Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
JP2018528206A (ja)	2015-08-28	2018-09-27	ノバルティスアーゲー	Ｍｄｍ２阻害剤およびその組み合わせ物
AR105889A1 (es)	2015-09-03	2017-11-22	Actelion Pharmaceuticals Ltd	Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
CN117737124A (zh)	2015-10-16	2024-03-22	菲特治疗公司	用于诱导和维护基态多能性的平台
BR112018008904A2 (pt)	2015-11-03	2018-11-27	Janssen Biotech Inc	anticorpos que se ligam especificamente a tim-3 e seus usos
AU2016349504B2 (en)	2015-11-04	2023-02-09	Fate Therapeutics, Inc.	Genomic engineering of pluripotent cells
US10858628B2 (en)	2015-11-04	2020-12-08	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
CA3007671A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
SG11201805186VA (en)	2016-01-20	2018-07-30	Fate Therapeutics Inc	Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A4 (en)	2016-01-20	2019-12-04	Fate Therapeutics, Inc.	COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
AR108257A1 (es)	2016-05-02	2018-08-01	Mei Pharma Inc	Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
SG11201810793XA (en)	2016-06-03	2018-12-28	Giordano Caponigro	Pharmaceutical combinations
CN109906224B (zh)	2016-06-20	2022-02-25	诺华股份有限公司	***吡啶化合物及其应用
WO2017221100A1 (en)	2016-06-20	2017-12-28	Novartis Ag	Imidazopyrimidine compounds useful for the treatment of cancer
US11091489B2 (en)	2016-06-20	2021-08-17	Novartis Ag	Crystalline forms of a triazolopyrimidine compound
EP3507367A4 (en)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018065924A1 (en) *	2016-10-04	2018-04-12	Sun Pharmaceutical Industries Limited	Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en)	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) *	2016-11-24	2021-07-30	中山大学	一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
JP7098615B2 (ja)	2016-12-05	2022-07-11	フェイトセラピューティクス，インコーポレイテッド	養子免疫療法における免疫細胞調節のための組成物および方法
EP3372624A1 (en)	2017-03-06	2018-09-12	Henkel AG & Co. KGaA	One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN109438362B (zh) *	2017-11-14	2020-07-21	深圳市塔吉瑞生物医药有限公司	一种取代的苯并咪唑化合物及包含该化合物的组合物
JP2021503478A (ja)	2017-11-16	2021-02-12	ノバルティスアーゲー	組み合わせ治療
TW201938165A (zh)	2017-12-18	2019-10-01	美商輝瑞股份有限公司	治療癌症的方法及組合療法
CA3094431C (en)	2018-03-19	2023-06-27	Taiho Pharmaceutical Co., Ltd.	Pharmaceutical composition including sodium alkyl sulfate
MX2020010437A (es)	2018-04-05	2021-01-29	Sumitomo Pharma Oncology Inc	Inhibidores de axl cinasa y uso de los mismos.
EP3802609A2 (en)	2018-05-24	2021-04-14	Janssen Biotech, Inc.	Psma binding agents and uses thereof
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021000805A (es)	2018-07-25	2021-05-12	Advanced Accelerator Applications Sa	Soluciones de complejos de radionuclidos estables y concentradas.
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
LT3837256T (lt)	2018-08-17	2023-06-12	Novartis Ag	Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai
JP7358484B2 (ja)	2018-09-25	2023-10-10	アドヴァンスド・アクセラレーター・アプリケーションズ・（イタリー）・エッセエッレエッレ	併用療法
US11572344B2 (en)	2018-11-20	2023-02-07	Nflection Therapeutics, Inc.	Cyanoaryl-aniline compounds for treatment of dermal disorders
AU2019402189B2 (en)	2018-12-20	2023-04-13	Novartis Ag	Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
EP3924351A4 (en)	2019-02-12	2022-12-21	Sumitomo Pharma Oncology, Inc.	FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
EA202192019A1 (ru)	2019-02-15	2021-11-02	Новартис Аг	Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
AU2020222346B2 (en)	2019-02-15	2021-12-09	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020245437A1 (en)	2019-03-22	2021-09-30	Sumitomo Pharma Oncology, Inc.	Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020212832A1 (en) *	2019-04-16	2020-10-22	Alembic Pharmaceuticals Limited	Process of preparation of benzimidazole compounds
CN113747944A (zh)	2019-04-19	2021-12-03	詹森生物科技公司	用抗psma/cd3抗体治疗***癌的方法
TWI817018B (zh)	2019-06-28	2023-10-01	美商艾瑞生藥股份有限公司	用於治療ｂｒａｆ相關的疾病和失調症之化合物
WO2021003417A1 (en)	2019-07-03	2021-01-07	Sumitomo Dainippon Pharma Oncology, Inc.	Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021116901A1 (en) *	2019-12-09	2021-06-17	Biocon Limited	Forms of binimetinib and process for preparation thereof
WO2021123996A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP2023517393A (ja) *	2020-03-17	2023-04-25	メッドシャインディスカバリーインコーポレイテッド	タンパク質分解調整剤およびその使用方法
WO2021206167A1 (ja)	2020-04-10	2021-10-14	大鵬薬品工業株式会社	３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
AU2021289163A1 (en)	2020-06-09	2022-12-22	Array Biopharma Inc.	4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
WO2021260528A1 (en)	2020-06-23	2021-12-30	Novartis Ag	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AR123185A1 (es)	2020-08-10	2022-11-09	Novartis Ag	Compuestos y composiciones para inhibir ezh2
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
WO2022043556A1 (en)	2020-08-31	2022-03-03	Novartis Ag	Stable radiopharmaceutical composition
WO2022043558A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4225307A1 (en)	2020-10-05	2023-08-16	Pierre Fabre Medicament	Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN112679438A (zh) *	2020-12-31	2021-04-20	武汉九州钰民医药科技有限公司	制备司美替尼的方法
CN112759552A (zh) *	2020-12-31	2021-05-07	武汉九州钰民医药科技有限公司	司美替尼的合成方法
EP4281069A1 (en) *	2021-01-21	2023-11-29	NFlection Therapeutics, Inc.	Processes for preparing pyrrolopyridine-aniline compounds
BR112023015097A2 (pt)	2021-01-28	2023-10-03	Janssen Biotech Inc	Proteínas de ligação a psma e usos das mesmas
WO2022169780A1 (en)	2021-02-02	2022-08-11	Les Laboratoires Servier	Selective bcl-xl protac compounds and methods of use
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309022A (zh)	2021-04-13	2023-03-01	美商努法倫特公司	用於治療具egfr突變之癌症之胺基取代雜環
EP4322953A1 (en) *	2021-04-15	2024-02-21	Ideaya Biosciences, Inc.	Combination therapy comprising a pkc inhibitor and a mek inhibitor
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN117642166A (zh)	2021-06-09	2024-03-01	中外制药株式会社	用于癌症治疗的组合疗法
WO2022262699A1 (zh) *	2021-06-17	2022-12-22	深圳市塔吉瑞生物医药有限公司	取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
CA3226162A1 (en)	2021-07-09	2023-01-12	Plexium, Inc.	Aryl compounds and pharmaceutical compositions that modulate ikzf2
AU2022383040A1 (en)	2021-11-04	2024-03-07	F. Hoffmann-La Roche Ag	Novel use of quinazolinone compound for the treatment of cancer
WO2023084489A1 (en)	2021-11-15	2023-05-19	Pfizer Inc.	Methods of treating coronavirus disease 2019
TW202342018A (zh)	2022-03-04	2023-11-01	美商奇奈特生物製藥公司	Mek激酶抑制劑
WO2023225336A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en)	2022-05-20	2023-11-23	Novartis Ag	Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023238000A1 (en) *	2022-06-06	2023-12-14	Glenmark Life Sciences Limited	Process for preparation of selumetinib and salts thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55501033A (xx)	1978-11-20	1980-11-27
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5250554A (en) *	1989-10-24	1993-10-05	Takeda Chemical Industries, Ltd.	Benzimidazole derivatives useful as angiotensin II inhibitors
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5218356A (en) *	1991-05-31	1993-06-08	Guenther Knapp	Wireless indoor data relay system
US5216003A (en) *	1992-01-02	1993-06-01	G. D. Searle & Co.	Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
EP0710654A4 (en)	1993-07-23	1996-08-28	Green Cross Corp	TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
EP0639573A1 (de)	1993-08-03	1995-02-22	Hoechst Aktiengesellschaft	Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
ZA953311B (en)	1994-04-29	1996-10-24	Lilly Co Eli	Non-peptidyl tachykinin receptor antagonists
US5520187A (en) *	1994-11-25	1996-05-28	General Electric Company	Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en)	1995-01-24	1996-06-11	Warner-Lambert Company	2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en)	1995-04-20	2001-07-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
US5972980A (en) *	1995-10-05	1999-10-26	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
ATE225343T1 (de)	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren
GB9600344D0 (en) *	1996-01-09	1996-03-13	Lilly Co Eli	Benzimidzolyl neuropeptide y receptor antagonists
HUP9903014A3 (en)	1996-07-18	2000-08-28	Pfizer	Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en)	1996-08-23	2000-11-28	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2277100C (en)	1997-01-06	2005-11-22	Pfizer Inc.	Cyclic sulfone derivatives
TR199901849T2 (xx)	1997-02-03	2000-02-21	Pfizer Products Inc.	Arils�lfonilamino hidroksamik asit t�revleri.
CA2279863A1 (en)	1997-02-07	1998-08-13	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en)	1997-02-11	2001-02-23	Pfizer	Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
UA73073C2 (uk)	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ES2274572T3 (es)	1997-07-01	2007-05-16	Warner-Lambert Company Llc	Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
US6310060B1 (en)	1998-06-24	2001-10-30	Warner-Lambert Company	2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
WO1999001426A1 (en)	1997-07-01	1999-01-14	Warner-Lambert Company	4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6506798B1 (en) *	1997-07-01	2003-01-14	Warner-Lambert Company	4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) *	1997-07-01	2004-11-23	Warner-Lambert Company	4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
US6534503B1 (en) *	1998-04-28	2003-03-18	Lion Bioscience Ag	Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en)	1998-09-25	1998-10-15	University Of Queensland, The	Synthesis of cyclic peptides
CA2358438A1 (en)	1999-01-07	2000-07-13	David Thomas Dudley	Antiviral method using mek inhibitors
AU2483000A (en)	1999-01-07	2000-07-24	Warner-Lambert Company	Treatment of asthma with mek inhibitors
CA2349832A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
ATE302193T1 (de) *	1999-01-13	2005-09-15	Warner Lambert Co	Benzoheterozyklen und ihre verwendung als mek inhibitoren
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
AU2482800A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
BR9916857A (pt)	1999-01-13	2001-12-04	Warner Lambert Co	4 heteroaril diarilaminas
JP2000204077A (ja)	1999-01-13	2000-07-25	Warner Lambert Co	ジアリ―ルアミン
CZ20012528A3 (cs)	1999-01-13	2002-06-12	Warner-Lambert Company	1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení
GB9910577D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
HUP0202319A3 (en)	1999-07-16	2004-12-28	Warner Lambert Co	Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
US7030119B1 (en) *	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
HUP0202623A3 (en)	1999-07-16	2003-03-28	Warner Lambert Co	Method for treating chronic pain using mek inhibitors
KR20020015379A (ko)	1999-07-16	2002-02-27	로즈 암스트롱, 크리스틴 에이. 트러트웨인	엠이케이 억제제를 사용하는 만성 동통의 치료방법
ATE250932T1 (de)	1999-07-16	2003-10-15	Warner Lambert Co	Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
WO2001021634A1 (en)	1999-09-21	2001-03-29	Lion Bioscience Ag	Benzimidazole derivatives and combinatorial libraries thereof
WO2001068619A1 (en)	2000-03-15	2001-09-20	Warner-Lambert Company	5-amide substituted diarylamines as mex inhibitors
EP1339702A1 (en)	2000-03-15	2003-09-03	Warner-Lambert Company	5-amide substituted diarylamines as mek inhibitors
AU2001273498B2 (en)	2000-07-19	2006-08-24	Warner-Lambert Company	Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PL360699A1 (en)	2000-08-25	2004-09-20	Warner-Lambert Company Llc.	Process for making n-aryl-anthranilic acids and their derivatives
US7067532B2 (en)	2000-11-02	2006-06-27	Astrazeneca	Substituted quinolines as antitumor agents
US20070004713A1 (en) *	2000-12-07	2007-01-04	Bernard Barlaam	Therapeutic benimidazole compounds
US7102009B2 (en) *	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
WO2002072548A2 (en) *	2001-03-09	2002-09-19	Ortho-Mcneil Pharmaceutical, Inc.	Heterocyclic compounds and their use as histamine h4 ligands.
US20040039208A1 (en)	2001-07-20	2004-02-26	Chen Michael Huai Gu	Process for making n-aryl-anthranilic acids and their derivatives
EP1427408A4 (en) *	2001-09-17	2005-10-26	Bristol Myers Squibb Co	CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003054180A1 (en)	2001-12-21	2003-07-03	Warner-Lambert Company Llc	Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
MXPA04005527A (es)	2002-01-23	2005-03-23	Warner Lambert Co	ESTERES HIDROXIMATO DEL áCIDO N-(4-FENIL SUSTITUIDO)-ANTRANILICO.
US7235537B2 (en) *	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
UA76837C2 (uk) *	2002-03-13	2006-09-15	Еррей Байофарма Інк.	N3 алкіловані похідні бензімідазолу як інгібітори мек
SG148857A1 (en)	2002-03-13	2009-01-29	Array Biopharma Inc	N3 alkylated benzimidazole derivatives as mek inhibitors
DE10238002A1 (de) *	2002-08-20	2004-03-04	Merck Patent Gmbh	Benzimidazolderivate
RU2005106274A (ru) *	2002-09-06	2005-11-10	Янссен Фармацевтика, Н.В. (Be)	Гетероциклические соединения
US20040127395A1 (en) *	2002-09-06	2004-07-01	Desai Pragnya J.	Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) *	2002-12-24	2009-09-01	Purdue Pharma, L.P.	Therapeutic agents useful for treating pain
CA2532067C (en)	2003-07-24	2010-12-21	Stephen Douglas Barrett	N-methyle-substituted benzamidazoles
DE102005032379A1 (de)	2005-07-08	2007-01-11	Conti Temic Microelectronic Gmbh	Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
EP2934515B1 (en)	2012-12-20	2018-04-04	Novartis AG	A pharmaceutical combination comprising binimetinib

2003
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/en not_active Revoked
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/en active Application Filing
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 CA CA002478374A patent/CA2478374C/en not_active Expired - Lifetime
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 EP EP03714148A patent/EP1482932B1/en not_active Expired - Lifetime
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/en active
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/en not_active Expired - Lifetime
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 EP EP09011389A patent/EP2130537B1/en not_active Expired - Lifetime
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/en not_active Expired - Lifetime
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/en active
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
2004
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Lifetime
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Lifetime
2011
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I1/el unknown

Also Published As

Publication number	Publication date
EP2275102B1 (en)	2015-07-29
TWI350285B (en)	2011-10-11
IS7442A (is)	2004-09-09
EP3000810A1 (en)	2016-03-30
US7425637B2 (en)	2008-09-16
IL204420A0 (en)	2011-07-31
AU2003218157A1 (en)	2003-09-29
LUC00100I2 (xx)	2020-01-23
AR090144A2 (es)	2014-10-22
DOP2013000023A (es)	2013-06-30
SI3000810T1 (sl)	2017-10-30
ES2549159T3 (es)	2015-10-23
RU2307831C9 (ru)	2008-06-10
MXPA04008893A (es)	2005-06-20
US7576114B2 (en)	2009-08-18
TW201031641A (en)	2010-09-01
AU2003218157C1 (en)	2011-11-24
US7777050B2 (en)	2010-08-17
IL163995A (en)	2010-11-30
US20080171778A1 (en)	2008-07-17
IS8959A (is)	2011-06-16
SI2275102T1 (sl)	2015-12-31
US7973170B2 (en)	2011-07-05
EP3000810B1 (en)	2017-07-19
EP2130536A1 (en)	2009-12-09
PT3000810T (pt)	2017-10-25
KR100984613B1 (ko)	2010-09-30
CN101633645B (zh)	2011-06-22
CA2478374A1 (en)	2003-09-25
PT2275102E (pt)	2015-10-27
LTC1482932I2 (lt)	2020-04-27
HUE025767T2 (en)	2016-05-30
IL204419A0 (en)	2011-07-31
US20100260714A1 (en)	2010-10-14
US20030232869A1 (en)	2003-12-18
IS8960A (is)	2011-06-16
HUS1900011I1 (hu)	2019-04-29
US20050143438A1 (en)	2005-06-30
CN1652776A (zh)	2005-08-10
KR100984573B1 (ko)	2010-09-30
EP2130537A1 (en)	2009-12-09
ES2407849T3 (es)	2013-06-14
LTPA2019007I1 (lt)	2019-03-25
US20120277277A1 (en)	2012-11-01
JP5102642B2 (ja)	2012-12-19
LUC00100I1 (xx)	2019-02-13
TWI343377B (en)	2011-06-11
HK1153139A1 (zh)	2012-03-23
CN101633644A (zh)	2010-01-27
TWI338685B (en)	2011-03-11
ES2635666T3 (es)	2017-10-04
PL233493B1 (pl)	2019-10-31
ES2335276T3 (es)	2010-03-24
BR122018007328B8 (pt)	2021-05-25
CY1109727T1 (el)	2014-09-10
EP2130536B1 (en)	2013-05-08
DK1482932T3 (da)	2010-02-01
DE60330227D1 (de)	2010-01-07
JP2008019277A (ja)	2008-01-31
PT2130537E (pt)	2012-12-20
KR20040094786A (ko)	2004-11-10
US8193231B2 (en)	2012-06-05
RU2307831C2 (ru)	2007-10-10
SG194238A1 (en)	2013-11-29
CN101486682B (zh)	2013-08-14
IS2990B (is)	2017-12-15
DK2275102T3 (en)	2015-11-02
PL401637A1 (pl)	2013-05-27
JP4093966B2 (ja)	2008-06-04
US20110158971A1 (en)	2011-06-30
IS2748B (is)	2011-08-15
EP2130537B1 (en)	2012-11-14
RU2004127926A (ru)	2005-06-27
BR122018007328B1 (pt)	2020-03-03
CN101486682A (zh)	2009-07-22
BE2019C510I2 (xx)	2022-05-19
US8178693B2 (en)	2012-05-15
PA8569301A1 (es)	2004-10-08
PL401638A1 (pl)	2013-05-27
AU2009222613B2 (en)	2011-06-16
PL233177B1 (pl)	2019-09-30
NL300974I2 (nl)	2022-04-06
US20080177082A1 (en)	2008-07-24
US8003805B2 (en)	2011-08-23
US8513293B2 (en)	2013-08-20
CY2019012I2 (el)	2020-05-29
PT1482932E (pt)	2010-01-12
NZ535158A (en)	2007-06-29
CY2019012I1 (el)	2020-05-29
JP2008163034A (ja)	2008-07-17
JP2005530709A (ja)	2005-10-13
US20100261718A1 (en)	2010-10-14
CN101633645A (zh)	2010-01-27
ZA200407220B (en)	2007-05-30
CL2012002380A1 (es)	2012-11-05
EP1482932B1 (en)	2009-11-25
US20100267710A1 (en)	2010-10-21
DK2130537T3 (da)	2013-02-18
TW200407129A (en)	2004-05-16
EP1482932A4 (en)	2006-04-05
EP2275102A1 (en)	2011-01-19
UA77765C2 (en)	2007-01-15
DK3000810T3 (en)	2017-10-16
JP2012224649A (ja)	2012-11-15
IS2999B (is)	2018-06-15
US8193229B2 (en)	2012-06-05
ES2394347T3 (es)	2013-01-30
CL2012002381A1 (es)	2012-11-05
CY1119136T1 (el)	2018-02-14
EP1482932A1 (en)	2004-12-08
PL401636A1 (pl)	2013-05-27
US20100261717A1 (en)	2010-10-14
DOP2003000613A (es)	2003-09-30
IS2998B (is)	2018-06-15
KR20100040759A (ko)	2010-04-20
AR090143A2 (es)	2014-10-22
KR20100040760A (ko)	2010-04-20
ATE449605T1 (de)	2009-12-15
SI1482932T1 (sl)	2010-02-26
IL204419A (en)	2012-12-31
AR038971A1 (es)	2005-02-02
KR100984595B1 (ko)	2010-09-30
CN101633644B (zh)	2012-05-09
JP5498546B2 (ja)	2014-05-21
PL401635A1 (pl)	2013-05-27
CA2478374C (en)	2009-01-06
AU2003218157B2 (en)	2009-07-09
IL204420A (en)	2012-12-31
DOP2011000110A (es)	2011-11-30
PL230179B1 (pl)	2018-09-28
PL377628A1 (pl)	2006-02-06
US20100267793A1 (en)	2010-10-21
DOP2011000109A (es)	2011-11-30
US8193230B2 (en)	2012-06-05
SG2013013339A (en)	2014-12-30
CN100519539C (zh)	2009-07-29
TW201031642A (en)	2010-09-01
WO2003077914A1 (en)	2003-09-25
HK1070823A1 (en)	2005-06-30
SI2130537T1 (sl)	2013-01-31
HK1141976A1 (en)	2010-11-26
IS8961A (is)	2011-06-16
AU2009222613A1 (en)	2009-10-29
SG148857A1 (en)	2009-01-29

Publication	Publication Date	Title
HUS1900011I1 (hu)	2019-04-29	N3 alkilált benzimidazol-származékok, mint MEK inhibitorok
IL163996A0 (en)	2005-12-18	N3 alkylated benzimidazole derivatives as mek inhibitors
IL173935A0 (en)	2006-07-05	N3 alkylated benzimidazole derivatives as mek inhibitors
IL165810A0 (en)	2006-01-15	Novel benzimidazole derivatives
HK1071360A1 (en)	2005-07-15	2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
HK1085735A1 (en)	2006-09-01	New benzimidazole derivatives
ATE386518T1 (de)	2008-03-15	Benzimidazolderivate
AU2003302238A8 (en)	2004-06-23	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003232362A8 (en)	2003-12-22	4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
IL169094A0 (en)	2007-07-04	1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors